

# UCSF

## UC San Francisco Previously Published Works

### Title

Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care.

### Permalink

<https://escholarship.org/uc/item/9b48t99p>

### Journal

JAMA internal medicine, 179(12)

### ISSN

2168-6106

### Authors

Cohen, Andrew J  
Brody, Hartley  
Patino, German  
et al.

### Publication Date

2019-12-01

### DOI

10.1001/jamainternmed.2019.3330

Peer reviewed

# Letters

## RESEARCH LETTER

### Use of an Online Crowdfunding Platform for Unmet Financial Obligations in Cancer Care

Technologic innovations, expensive new therapies, and improved access to treatment have all contributed to the rising costs of oncologic care in the United States.<sup>1</sup> The financial consequences for patients and their families are substantial. Patients with cancer often borrow money, avoid leisure activities, decrease food spending, sell possessions, go into debt, and/or declare bankruptcy,<sup>2</sup> and they are at greater risk for disability or unemployment.<sup>3</sup> These consequences are particularly great for patients who are underinsured or uninsured. Recently, online crowdfunding platforms are being increasingly used to supplement insurance and defray expenses, even for experimental and unproven treatments.<sup>4</sup> We sought to characterize the use of crowdfunding to support oncology care needs, including any association between insurance status and other characteristics.

**Methods** | We identified the top 20 most prevalent cancers in the United States using data from the [National Cancer Institute](#). Each cancer and US state was queried on the GoFundMe platform ([www.gofundme.com](http://www.gofundme.com)) for 1000 individual searches (50 states × 20 top cancers = 1000 batches of searches). Using custom code for web scraping (software used to abstract and assemble website data for analysis), we identified 37 344 cancer campaigns on October 7, 2018. We used a randomizer to select 1035 campaigns, which we studied in detail. Narratives report details regarding a patient's oncologic treatment and personal and financial life. We selected variables of interest using a roundtable discussion among all authors and 2 rounds of iterative testing to ensure consensus and reproducibility in extracting data. We determined insurance status from campaign author self-reporting and defined the underinsured as those who stated that they were underinsured or uninsured. The institutional review board at the University of California, San Francisco deemed this study exempt because all data were publicly available.

Interrater reliability for collected clinical and financial details exceeded  $\kappa > 0.81$ . Descriptive statistics,  $\chi^2$ , Fisher exact, and Kruskal-Wallis testing were used to compare characteristics by insurance status as well as associations between reported variables and donation totals using Stata 15 software (StataCorp). *P* values < .05 were considered statistically significant.

**Results** | Campaigns commonly described details regarding age, employment status, cancer type, treatment plans, and prognosis (Table). The median fund-raising goal and donations obtained were \$10 000 (interquartile range [IQR], \$5000-\$20 000) and \$2125 [IQR, \$860-\$5475], respectively.

The most common campaign purposes were paying medical bills (n = 424 of 1035 [41.0%]), medical travel (n = 262 [25.3%]) and nonmedical bills (n = 240 [23.2%]), with 18 (1.7%) posters mentioning alternative treatments (Figure). Campaigns for underinsured patients requested \$10 000 more on average than those that did not mention insurance. Campaigns with underinsured patients made up 26.2% (n = 271) of the population and were more likely to seek funds for unpaid medical bills compared with those that did not mention insurance (n = 178 of 271 [65.7%] vs n = 245 of 764 [32.1%], *P* < .01). Posters received approximately a quarter of their requested goal, independent of insurance status (Table). The underinsured, compared with those not mentioning insurance, reported unstable employment (n = 107 of 271 [39.8%] vs n = 214 of 764 [28.0%], *P* < .01) and were more likely to mention prior surgical treatment (n = 105 of 271 [38.8%] vs n = 214 of 764 [28.0%], *P* < .01). There were no significant differences in patient age, sex, type of cancer, or insurance status with regard to donation totals.

**Discussion** | We have provided a detailed accounting of the characteristics of patients using a crowdfunding platform to support oncologic financial needs. The underinsured seek but do not receive higher donation amounts. Although the Affordable Care Act reduced the uninsured rate, cost containment measures have not been realized by all patients.<sup>5</sup> In this cohort, patients reported multiple competing financial needs, but most pressing were unpaid medical bills, which may represent copays, out-of-pocket drug costs, or high deductibles. Medical travel costs also were highly cited; we speculate that regionalization of oncologic care may improve outcomes but increase the financial burden on patients.<sup>6</sup> Limitations of the present study include generalizability to other patients, inability to determine the veracity of online claims, and determination of insurance status by narrative self-report. Nonetheless, these results suggest that the financial burden of health care requires increasing attention and advocacy.

Andrew J. Cohen, MD  
Hartley Brody, BS  
German Patino, MD  
Medina Ndoe, MD  
Aron Liaw, MD  
Christi Butler, MD  
Benjamin N. Breyer, MD

**Author Affiliations:** Department of Urology, University of California, San Francisco, San Francisco (Cohen, Brody, Patino, Ndoe, Liaw, Butler, Breyer); Hospital Universitario San Ignacio, Bogota, Colombia (Patino); Department of Biostatistics and Epidemiology, University of California, San Francisco, San Francisco (Breyer).

**Accepted for Publication:** June 14, 2019.

Table. Posted Cancer Specifics Stratified by Insurance Status

Characteristic	No. of Campaigns (%) (n = 1035) <sup>a</sup>	Campaigns With No Mention of Insurance, No. (%) (n = 764)	Campaigns for Underinsured/ Uninsured Patients, No. (%) (n = 271)	P Value
Demographic Characteristics				
Female sex	578 (56.1)	429 (56.5)	149 (55.0)	.75
Patient age group				
Adult (≥18 y)	881 (85.1)	641 (83.9)	240 (88.6)	.09
Child (<18 y)	100 (9.7)	83 (10.9)	17 (6.3)	
Clinical Characteristics <sup>b</sup>				
Cancer type				
Breast	189 (18.3)	142 (18.6)	47 (17.3)	.61
Leukemia	135 (13.0)	105 (13.7)	30 (11.1)	
Lung	113 (10.9)	82 (10.7)	31 (11.4)	
Colon	72 (7.0)	51 (6.7)	21 (7.8)	
Pancreatic	52 (5.0)	36 (4.7)	16 (5.9)	
Brain	43 (4.2)	36 (4.7)	7 (2.6)	
Liver	43 (4.2)	31 (4.1)	12 (4.4)	
Bone	28 (2.7)	23 (3.0)	5 (1.9)	
Other <sup>c</sup>	360 (34.8)	258 (33.8)	102 (36.6)	
Stage				
I	15 (1.5)	9 (1.2)	6 (2.4)	.05
II or III	102 (10.1)	65 (8.8)	37 (13.9)	
IV or higher	320 (31.7)	236 (31.8)	84 (31.5)	
Past treatment				
Chemotherapy	434 (41.9)	314 (41.1)	120 (44.3)	.36
Radiation	145 (14.0)	99 (13.0)	46 (17.0)	.10
Surgery	319 (30.8)	214 (28.0)	105 (38.8)	<.01
Future treatment				
Chemotherapy	230 (22.2)	151 (19.8)	79 (29.2)	<.01
Radiation	92 (8.9)	61 (8.0)	31 (11.4)	.09
Surgery	121 (11.7)	75 (9.8)	46 (17.0)	<.01
Immunotherapy	15 (1.5)	7 (0.9)	8 (3.0)	.03
Alternative medicine	45 (4.4)	34 (4.5)	11 (4.1)	.79
Family Characteristics				
Loss of occupation	318 (31.0)	211 (28.0)	107 (39.8)	<.01
Patient is primary wage earner	184 (18.0)	113 (15.0)	71 (26.4)	<.01
Patient with child <18 y	155 (30.0)	106 (28.2)	49 (34.8)	.08
Social Network Characteristics				
Campaign author				
Third party	342 (33.0)	257 (33.6)	85 (31.4)	.03
Unknown	149 (14.4)	120 (15.7)	29 (10.7)	
Family other	156 (15.1)	119 (15.6)	37 (13.7)	
Child	162 (15.7)	118 (15.5)	44 (16.2)	
Self	134 (13.0)	84 (11.0)	50 (18.5)	
Parent	49 (4.7)	36 (4.7)	13 (4.8)	
Spouse	43 (4.2)	30 (3.9)	13 (4.8)	
Online shares <sup>d</sup>				
Mean	366	376	338	.18
Median (IQR)	187 (84-408)	182 (74-394)	205 (98-438)	

(continued)

Table. Posted Cancer Specifics Stratified by Insurance Status (continued)

Characteristic	No. of Campaigns (%) (n = 1035) <sup>a</sup>	Campaigns With No Mention of Insurance, No. (%) (n = 764)	Campaigns for Underinsured/Uninsured Patients, No. (%) (n = 271)	P Value
Fund-raising, \$				
Goal				
Mean	21 189	18 490	28 773	<.01
Median (IQR)	10 000 (5000-20 000)	10 000 (5000-20 000)	10 000 (6000-25 000)	
Raised				
Mean	5261	5197	5439	.20
Median (IQR)	2125 (860-5475)	2135 (872-5543)	2109 (800-5270)	

Abbreviation: IQR, interquartile range.


<sup>a</sup> Column percentage may not equal 100% owing to a lack of mention in online campaigns or in the case of past or future treatment (multiple simultaneous treatments).

<sup>b</sup> Because the table reports mentions in online campaigns, absence does not necessarily equate with true absence of a characteristic.

<sup>c</sup> Other includes bladder, cervical, kidney, melanoma, non-Hodgkin lymphoma, oral cancer, ovarian, prostate, rectal, skin, stomach, thyroid, uterine, testicular, and rare cancers.

<sup>d</sup> Number of campaign online social media shares as reported by the online crowdfunding platform.

Figure. Stated Purpose for Requested Funds on an Online Crowdfunding Platform



Dots represent overlapping reasons for seeking money on an online crowdfunding platform. Overlapping mentions of 3 or fewer are not shown. The top bar graph provides the frequency of each combination, whereas the left bar graph summarizes totals.

**Corresponding Author:** Benjamin N. Breyer, MD, MAS, FACS, University of California, San Francisco, Zuckerberg San Francisco General Hospital and Trauma Center, 1001 Potrero, Ste 3A, San Francisco, CA 94110 ([benjamin.breyer@ucsf.edu](mailto:benjamin.breyer@ucsf.edu)).

**Published Online:** September 9, 2019. doi:[10.1001/jamainternmed.2019.3330](https://doi.org/10.1001/jamainternmed.2019.3330)

**Author Contributions:** Dr Breyer had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Cohen, Liaw, Breyer.

**Acquisition, analysis, or interpretation of data:** Cohen, Brody, Patino, Ndoeye,

Liaw, Butler.

*Drafting of the manuscript:* Cohen, Brody, Ndoye.

*Critical revision of the manuscript for important intellectual content:* Cohen, Patino, Liaw, Butler, Breyer.

*Statistical analysis:* Cohen.

*Administrative, technical, or material support:* Brody, Patino, Liaw.

*Study supervision:* Cohen, Patino, Breyer.

*Other:* Ndoye.

**Conflict of Interest Disclosures:** None reported.

**Funding/Support:** The philanthropy of the Alafi Fund, Russell and Sara Hirsch, and Jonathan Kaplan supported this work (Dr Breyer).

**Role of the Funder/Sponsor:** The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We thank Kirkpatrick B. Fergus, BS; Jorge Mena, BS; Austin Lee, BS; Jeremy Weiser, BS; and Kelly Johnson, BS, from the Department of Urology, University of California, San Francisco for their contributions to the development and completion of this research project; they received no compensation for their contributions.

1. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. *J Natl Cancer Inst.* 2011;103(2):117-128. doi:10.1093/jnci/djq495

2. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. *Health Aff (Millwood).* 2013;32(6):1143-1152. doi:10.1377/hlthaff.2012.1263

3. Altice CK, Banegas MP, Tucker-Seeley RD, Yabroff KR. Financial hardships experienced by cancer survivors: a systematic review. *J Natl Cancer Inst.* 2016;109(2):djw205. doi:10.1093/jnci/djw205

4. Vox F, Folkers KM, Turi A, Caplan AL. Medical crowdfunding for scientifically unsupported or potentially dangerous treatments. *JAMA.* 2018;320(16):1705-1706. doi:10.1001/jama.2018.10264

5. Obama B. United States health care reform: progress to date and next steps. *JAMA.* 2016;316(5):525-532. doi:10.1001/jama.2016.9797

6. Lumpkin S, Stitzenberg K. Regionalization and its alternatives. *Surg Oncol Clin N Am.* 2018;27(4):685-704. doi:10.1016/j.soc.2018.05.009